Home
Conditions
Refractory Follicular Lymphoma

Clinical trial condition

Refractory Follicular Lymphoma

Explore clinical trials studying Refractory Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

35 public trials 6 recruiting studies

Refine in advanced search Browse all conditions

Refractory Follicular Lymphoma trial results

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

NCT04587687

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Recruiting

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

NCT06948786

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +59 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

NCT05848765

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: NHS Grampian Aberdeen, United Kingdom

Belfast Health & Social Care Trust Belfast, United Kingdom

University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom

Blackpool Teaching Hospitals NHS Foundation Trust Blackpool, United Kingdom

View all 25 locations

View Trial Details

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887

Conditions: B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +35 more
Locations: Mayo Clinic in Florida Jacksonville, Florida, United States

View Trial Details

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

NCT04205409

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +46 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

NCT02332980

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +48 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553

Conditions: Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

City of Hope Comprehensive Cancer Center Duarte, California, United States

UC San Diego Moores Cancer Center La Jolla, California, United States

Los Angeles General Medical Center Los Angeles, California, United States

View all 24 locations

View Trial Details

Completed

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: Georgetown Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States

John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States

Seattle Cancer Care Alliance Seattle, Washington, United States

View Trial Details

Refractory Follicular Lymphoma

Refractory Follicular Lymphoma trial results

Related conditions